Dmard

Living under COVID-19 lockdown was associated with a higher rate of joint inflammation in children with juvenile idiopathic arthritis, according to data from an Italian cohort published in Arthritis Care & Research.

Maximizing the disease-modifying benefits of methotrexate is one of the core principles behind the 2021 American College of Rheumatology rheumatoid arthritis guidelines.

The use of biological disease-modifying antirheumatic drugs in patients with psoriasis reduces the risk for psoriatic arthritis, according to data published in the Annals of the Rheumatic Diseases.

Patients with elderly-onset rheumatoid arthritis have similar disease activity and adverse-event risk responses to biologics as nonelderly patients, according to data published in The Journal of Rheumatology.

Despite a low number of major adverse cardiovascular events overall, patients with psoriatic arthritis who newly start IL-12/23 or IL-17 inhibitors have a greater cardiovascular risk than those who begin TNF inhibitors, according to data.

Both ustekinumab and TNF inhibitors demonstrate significant improvement in psoriatic arthritis disease activity, with similar positive results in minimal and low disease activity, and remission, after 6 months, according to data.

Women with inflammatory arthritis may be rejecting or discontinuing medications during pregnancy and lactation, due, in part, to inconsistent information from their providers about the safety of arthritis medications, according to findings in ACR Open Rheumatology.

Methotrexate increases the probability of remission with adalimumab or infliximab by 50% in patients with psoriatic arthritis, versus TNF-inhibitor monotherapy, according to data published in the Annals of the Rheumatic Diseases.

Pharmaceutical industry payments to U.S. rheumatologists topped $220 million from 2014 through 2019, with 78% of that total going to just 6% of recipients, according to an analysis of CMS data published in Arthritis & Rheumatology.

Three strategies aimed at starting patients with polyarticular juvenile idiopathic arthritis on different combinations of DMARDs and biologics resulted in similar rates of clinically inactive disease without glucocorticoids at 12 months, according to data.